PB1046 for Heart Failure
Heart failure is the most common cause of hospitalization in people over age 65 and is associated with high mortality. Heart failure is not a single disease, but a complex syndrome of cardiovascular abnormalities that can lead to myocardial dysfunction, circulatory insufficiency and multi-organ congestion. Disease progression can lead to the worsening of symptoms, functional decline and increased mortality.
The known effects of VIP indicate that it may provide significant therapeutic benefit to heart failure patients, including myocardial contractility and relaxation, potent vasodilation to decrease blood pressure, and the prevention of tissue scarring.
PB1046 has been shown to improve overall cardiovascular function in multiple animal models of heart failure. This may translate into a reduction of heart failure-related symptoms, hospitalization and mortality, and improvement in patient functional status.
PhaseBio recently concluded a Phase 2a multiple ascending dose trial of PB1046 in patients with heart failure with reduced ejection fraction.